FDA advisors back approval of Sanofi’s new diabetes drug
Sanofi’s new diabetes therapy has taken a big step towards clearance in the US after winning backing from regulatory advisors.
Read More
Tag: Lyxumia
- MIT’s new MRI brain light-detecting technique could support brain cell studies
- PharmaTimes MSEA and NIEA awards are open for entry
- BBSRC invests £48m in Babraham Institute to advance lifelong health research
- NHS reduces long waits for cancer care and achieves faster ambulance responses
- MHRA’s AI Airlock to address challenges for regulating AI medical devices
